Market Place
Sourcing Support
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
18 Nov 2024 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
GLOBENEWSWIRE
BioCryst Reports Q3 2024 Results and Business Update
04 Nov 2024 //
GLOBENEWSWIRE
BioCryst Presents Real-World Evidence For ORLADEYO®
24 Oct 2024 //
GLOBENEWSWIRE
BioCryst to Report Third Quarter 2024 Financial Results on November 4
21 Oct 2024 //
GLOBENEWSWIRE
BioCryst To Present Evidence Showing Reduced Visits After ORLADEYO®
14 Oct 2024 //
GLOBENEWSWIRE
BioCryst Presents HAE Prophylaxis Data At ACAAI 2024 Meeting
10 Oct 2024 //
GLOBENEWSWIRE
BioCryst Reports Grants Under Nasdaq Rule 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
BioCryst Begins Phase 1 Trial for Netherton Syndrome
02 Oct 2024 //
GLOBENEWSWIRE
U.S. Government Awards BioCryst $69 Million RAPIVAB Contract
30 Sep 2024 //
GLOBENEWSWIRE
BioCryst Completes pCPA Negotiations for ORLADEYO®
17 Sep 2024 //
GLOBENEWSWIRE
BioCryst Presents New Orladeyo Data At Bradykinin Symposium
06 Sep 2024 //
GLOBENEWSWIRE
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
05 Sep 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing
04 Sep 2024 //
GLOBENEWSWIRE
BioCryst Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2024 //
GLOBENEWSWIRE
BioCryst to Report Second Quarter 2024 Financial Results on August 5
22 Jul 2024 //
GLOBENEWSWIRE
ORLADEYO® (berotralstat) Approved in Peru
09 Jul 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jul 2024 //
GLOBENEWSWIRE
KalVista files first oral on-demand HAE drug with FDA
18 Jun 2024 //
PHARMAPHORUM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jun 2024 //
GLOBENEWSWIRE
BioCryst To Present Data At EAACI 2024 Meeting
14 May 2024 //
GLOBENEWSWIRE
BioCryst ORLADEYO Real-World Evidence At HAE Conference
09 May 2024 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
07 May 2024 //
GLOBENEWSWIRE
BioCryst Reports Q1 2024 Results, Business Updates
06 May 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 //
GLOBENEWSWIRE
BioCryst to Report First Quarter 2024 Financial Results on May 6
22 Apr 2024 //
GLOBENEWSWIRE
BioCryst`s ORLADEYO Approved in Brazil
17 Apr 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
25 Mar 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
GLOBENEWSWIRE
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
BioCryst Presents Data Showing HAE Attack Reductions After Beginning ORLADEYO
23 Feb 2024 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
21 Feb 2024 //
GLOBENEWSWIRE
BioCryst Launches ORLADEYO® (berotralstat) in Italy
19 Feb 2024 //
GLOBENEWSWIRE
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
12 Feb 2024 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data
05 Feb 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
BioCryst Announces Full Year 2023 ORLADEYO Net Revenue of $325 Million
05 Jan 2024 //
GLOBENEWSWIRE
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jan 2024 //
GLOBENEWSWIRE
BioCryst Announces Publication of Data from Trial of ORLADEYO
19 Dec 2023 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2023 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO by the ANMAT in Argentina
29 Nov 2023 //
GLOBENEWSWIRE
BioCryst Launches ORLADEYO® (berotralstat) in Spain
21 Nov 2023 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
21 Nov 2023 //
GLOBENEWSWIRE
BioCryst Presents Data Showing Reduced Attack Rates in Patients with HAE
10 Nov 2023 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2023 //
GLOBENEWSWIRE
BioCryst and Clearside Biomedical Enter Partnership
03 Nov 2023 //
GLOBENEWSWIRE
BioCryst R&D Day Highlights Pipeline of First-in-Class/Best-in-Class Therapies
03 Nov 2023 //
GLOBENEWSWIRE
BioCryst Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO Data at Annual Scientific Meeting
27 Oct 2023 //
GLOBENEWSWIRE
BioCryst Begins Enrollment in Trial to Confirm Safe Dose of BCX10013
26 Oct 2023 //
GLOBENEWSWIRE
BioCryst to Host R&D Day on November 3
20 Oct 2023 //
GLOBENEWSWIRE
BioCryst to Report Third Quarter 2023 Financial Results on November 2
19 Oct 2023 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2023 //
GLOBENEWSWIRE
INESSS Recommends Public Reimbursement for BioCryst`s ORLADEYO
18 Sep 2023 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
23 Aug 2023 //
GLOBENEWSWIRE
